Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors
- 20 Downloads
Selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), like the tricyclic antidepressants and monoamine oxidase inhibitors, are associated with a well recognised syndrome following discontinuation or dose reduction. There appear to be differences in the incidence of discontinuation syndromes within the class of SSRIs. Published case reports and adverse drug reaction reports both suggest the highest incidence of the syndrome with paroxetine and the lowest incidence with fluoxetine, while other SSRIs are associated with an intermediate incidence. Open label comparison and placebo-controlled double-blind studies support this contention.
There is little evidence to separate discontinuation syndromes with different SSRIs on the basis of clinical presentation. Although the pathogenesis of SSRI discontinuation syndromes is unknown, both pharmacodynamic and pharmacokinetic factors may explain differences in incidence with individual SSRIs.
SSRI discontinuation syndromes are usually mild and transient, and prevention is the most effective management strategy.
Unable to display preview. Download preview PDF.
- 1.Kuhn R. On the treatment of depressive states with an iminodibenzyl derivative (G 22355). Nederlansch Tijdschrift Voor Geneeskunde 1957; 87: 1135Google Scholar
- 2.Lader M. Benzodiazepine withdrawal states. In: Trimble MR, editor. Benzodiazepines divided. New York (NY): John Wiley &Sons, 1983: 17–31Google Scholar
- 4.Gillespie C, Wildgust HJ, Haddad P, et al. SSRIs and withdrawal syndrome. Presented at the X World Congress of Psychiatry, 1996 Aug; Madrid, 23–28Google Scholar
- 5.Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychol 1997; 58 Suppl. 7: 17–22Google Scholar
- 6.Adverse Drug Reactions Advisory Committee. Aust Adv Drug React Bull 1996; 15: 3Google Scholar
- 16.Richelson E. The pharmacology of antidepressants at the synapse: focus on the newer compounds. J Clin Psych 1994; 55 Suppl. A: 34–9Google Scholar
- 17.Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. 1st ed. Caddo (OK): Professional Communications Inc., 1996Google Scholar